Antibody (IgM and IgG) responses to VNTR in patients immunized with M-FP. Representative examples from patients 3, 4, 5, 7, 8, 10 and 11. 1 = first injection; 2 = week 6 (2 weeks after the third injection); 3 = week 12 (2 weeks after the sixth injection); 4 = 6 months (3 months after the seventh injection); 6 = 1 year and 3 months after the final (ninth) injection; 7 = 2 years, and 1 year and 3 months after the final injection. A positive control serum was selected from a panel, being from a patient previously immunized with M-FP (IFCM10_#2EC) who had developed an anti-VNTR antibody response. Negative control serum was selected from a panel, being from a normal individual (ARI_#S2P) with no detectable anti-VNTR antibody. The antibody reactions are presented as percentage positive of test sera compared with positive control sera (where the negative control serum reaction was <15% of positive serum). M-FP, oxidized mannan conjugated to MUC1 fusion protein; VNTR, variable number of tandem repeats (from MUC1 sequence).